Prognostic Significance of Growth Factors and the Urokinase-Type Plasminogen Activator System in Pancreatic Ductal Adenocarcinoma

Objectives: To determine the diagnostic and prognostic significance of growth factors and the urokinase-type plasminogen activator (uPA) system in pancreatic ductal adenocarcinoma (PDAC) using a multigene assay. Methods: Messenger RNA (mRNA) expression of 15 genes from epidermal growth factor receptor, insulin-like growth factor (IGF), and uPA families were measured in 46 PDAC tissue samples using quantitative real-time reverse transcription-polymerase chain reaction. These results were compared with those of the uninvolved adjacent (AP) tissue and benign mucinous cystadenomas (BMC). The mRNA expression was evaluated using logistic regression and receiver operating characteristic area under the curve (ROC AUC) analyses. Their relationship with prognosis was tested by Cox regression multivariate analysis. Results: All genes were overexpressed in most of the PDAC tissue. When compared with AP tissue, the median expression values for IGF-binding protein 3 (IGFBP-3) and uPA receptor (uPAR) was 9.8- and 9.6-fold, respectively. Expression levels of uPA, uPAR, IGF-I, and IGFBP-3 mRNA were significantly greater in PDAC than in BMC. The IGFBP-3 mRNA expression demonstrated greatest ROC AUC values for PDAC versus AP tissue (ROC AUC, 0.745; 95% confidence interval [CI], 0.65-0.86); whereas ROC AUC values were greatest for uPAR when PDAC was compared with BMC (ROC AUC, 0.846; 95% CI, 0.76-0.94). The combination of uPA, uPAR, and IGF-I significantly improved discriminatory power (ROC AUC, 0.965; 95% CI, 0.93-1.00). The IGFBP-3, uPA, plasminogen activator inhibitor-2, and International Union Against Cancer stage had a significant influence on survival, but the effect of IGFBP-3 was lost after multivariate stepwise analysis. Conclusions: These results indicate that there is an influence of IGF system in tumor progression from BMC to PDAC, whereas the uPA/uPAR system has the greater influence on survival in PDAC.

[1]  S. Loening,et al.  Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder , 2006, BMC urology.

[2]  Susan R. Wilson,et al.  Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology. , 2006, Gastroenterology.

[3]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[4]  X. Tan,et al.  Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells. , 2006, International journal of oncology.

[5]  C P Neal,et al.  Molecular prognostic markers in pancreatic cancer: a systematic review. , 2005, European journal of cancer.

[6]  C. Scarlett,et al.  Assessment of HER-2 Status in Pancreatic Adenocarcinoma: Correlation of Immunohistochemistry, Quantitative Real-Time RT-PCR, and FISH With Aneuploidy and Survival , 2005, The American journal of surgical pathology.

[7]  Yong Li,et al.  Significant overexpression of urokinase‐type plasminogen activator in pancreatic adenocarcinoma using real‐time quantitative reverse transcription polymerase chain reaction , 2005, Journal of gastroenterology and hepatology.

[8]  J. Hoheisel,et al.  DNA Microarray Analysis of Pancreatic Malignancies , 2004, Pancreatology.

[9]  A. Tamakoshi,et al.  Serum insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3, and the risk of pancreatic cancer death , 2004, International journal of cancer.

[10]  H. Khamis,et al.  Simple solution to a common statistical problem: interpreting multiple tests. , 2004, Clinical therapeutics.

[11]  Jun Lu,et al.  Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. , 2003, World journal of gastroenterology.

[12]  A. Moorman,et al.  Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data , 2003, Neuroscience Letters.

[13]  R. Bast,et al.  Heregulin-induced apoptosis , 2002, Apoptosis.

[14]  E. Karna,et al.  Serum and tissue level of insulin‐like growth factor‐I (IGF‐I) and IGF‐I binding proteins as an index of pancreatitis and pancreatic cancer , 2002, International journal of experimental pathology.

[15]  M. Büchler,et al.  ErbB2 oncogene expression supports the acute pancreatitis–chronic pancreatitis sequence , 2002, Virchows Archiv.

[16]  C. Compton,et al.  TNM residual tumor classification revisited , 2002, Cancer.

[17]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[18]  D. Montefiori,et al.  Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin. , 2001, The Journal of infectious diseases.

[19]  L. Caskey,et al.  HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells , 2001, Molecular and Cellular Biology.

[20]  A. Richter,et al.  Personal observations, opinions, and approaches to cancer of the pancreas and the periampullary area. , 2001, The Surgical clinics of North America.

[21]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[22]  R. Hruban,et al.  Can we screen high‐risk individuals to detect early pancreatic carcinoma? , 2000, Journal of surgical oncology.

[23]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[24]  G. Sakorafas,et al.  Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. , 2000, Cancer treatment reviews.

[25]  H. Friess,et al.  Growth Factors and Cytokines in Pancreatic Carcinogenesis , 1999, Annals of the New York Academy of Sciences.

[26]  H. Friess,et al.  ErbB‐4 mRNA expression is decreased in non‐metastatic pancreatic cancer , 1999, International journal of cancer.

[27]  M. Korc,et al.  Altered Expression of Insulin‐like Growth Factor II Receptor in Human Pancreatic Cancer , 1997, Pancreas.

[28]  H. Friess,et al.  Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  H. Friess,et al.  Cripto, a member of the epidermal growth factor family, is over‐expressed in human pancreatic cancer and chronic pancreatitis , 1994, International journal of cancer.

[30]  H. Friess,et al.  Overexpression of HER2/neu oncogene in human pancreatic carcinoma. , 1993, Human pathology.

[31]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[32]  A. James.  A note on the linear relation between lactate redox potential and the hydrogen shuttle flux. , 1982, Journal of theoretical biology.

[33]  P. Hammel.  [Pancreatic cancer: what is new in 2005?]. , 2006, Bulletin du Cancer.

[34]  M. Schindl.  High Expression of Plasminogen Activator Inhibitor-2 (PAI-2) is a Predictor of Improved Survival in Patients with Pancreatic Adenocarcinoma , 2006, World Journal of Surgery.

[35]  P. Hammel.  Cancer du pancréas : quoi de neuf en 2005 ? , 2006 .

[36]  M. Imamura,et al.  Changing Treatment Strategy for Gastrinoma in Patients with Zollinger-Ellison Syndrome , 2005, World Journal of Surgery.

[37]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[38]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[39]  H. Friess,et al.  Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. , 1997, British Journal of Cancer.